Combined-modality therapy with sphincter-preserving total mesorectal excision for locally advanced rectal cancer: Patient's age and long-term outcome

Journal of Gastrointestinal and Liver Diseases

Volumn 17, Issue 1, 2008, Pages 49-52

  Szynglarewicz, Bartlomiej ^b   Matkowski, Rafal ^a,b   Maciejczyk, Adam ^b   Kasprzak, Piotr ^b   Forgacz, Jozef ^b   Pudelko, Marek ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Wroclaw   (Poland)

Author keywords

Anterior resection; Combined modality therapy; Rectal cancer; Total mesorectal excision

Indexed keywords

ANTIINFECTIVE AGENT; FLUOROURACIL; FOLINIC ACID;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; RECTUM CANCER; RECTUM RESECTION; TUMOR GROWTH; TUMOR LOCALIZATION;

AGE FACTORS; AGED; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECTAL NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 42449154705     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wibe A, Syse A, Andersen E, et al. Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum: anterior vs. abdominoperineal resection. Dis Colon Rectum 2004; 47: 48-58.
2. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery- the clue to pelvic recurrence? Br J Surg 1982; 69: 613-616.
3. Simunovic M, Sexton R, Rempel E, Moran BJ, Heald RJ. Optimal preoperative assessment and surgery for rectal cancer may greatly limit the need for radiotherapy. Br J Surg 2003; 90: 999-1003.
4. Van Lingen CP, Zeebregts CJ, Gerritsen JJ, Mulder HJ, Mastboom WJ, Klaase JM. Local recurrence of rectal cancer after total mesorectal excision without preoperative radiotherapy. Int J Gastrointest Cancer 2003; 34: 129-134.
5. Suh KW, Kim BW, Chun M, Lim HY. Is postoperative radiotherapy useful for the rectal carcinoma in the era of total mesorectal excision? Hepatogastroenterology 2002; 49: 399-403.
6. Merchant NB, Guillem JG, Paty PB, et al. T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 1999; 3: 642-647.
7. Cecil TD, Sexton R, Moran BJ, Heald RJ. Total mesorectal excision results in low local recurrence rates in lymph node-positive rectal cancer. Dis Colon Rectum 2004; 47: 1145-1149.
8. Delaney CP, Lavery IC, Brenner A, et al. Preoperative radiotherapy improves survival for patients undergoing total mesorectal excision for stage T3 low rectal cancer. Ann Surg 2002; 236: 203-207.
9. Colquhoun P, Wexner SD, Cohen A. Adjuvant therapy is valuable in the treatment of rectal cancer despite total mesorectal excision. J Surg Oncol 2003; 83: 133-139.
10. Rodel C, Sauer R. Radiotherapy and concurrent radiochemotherapy for rectal cancer. Surg Oncol 2004; 13: 93-101.
11. Sauer R. Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer. Pathol Oncol Res 2002; 8: 7-17.
12. Osian G, Procopciuc L, Vlad L. MTHFR polymorphisms as prognostic factors in sporadic colorectal cancer. J Gastrointestin Liver Dis 2007; 16: 251-256.
13. Akkiprik M, Ataizi-Celikel C, Dusuceli F, et al. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers. J Gastrointestin Liver Dis 2007; 16: 11-17.
14. Seicean R, Funariu G, Seicean A. Molecular prognostic factors in rectal cancer. Rom J Gastroenterol 2004; 13: 223-231.
15. Osian G, Procopciuc L, Vlad L. NAT2 gene polymorphism and sporadic colorectal cancer: prevalence, tumour stage and prognosis. A preliminary study in 70 patients. J Gastrointestin Liver Dis 2006; 15: 347-353.
16. Szynglarewicz B, Matkowski R, Forgacz J, et al. Clinical factors in prediction of prognosis after anterior resection with total mesorectal excision for carcinoma of the rectum. Oncol Rep 2007; 17: 471-475.
17. Jass JR, Love SB, Northover JM. A new prognostic classification for rectal cancer. Lancet 1987; 1: 1303-1306.
18. Li Destri G, Rinzivillo C, Vasquez E, di Cataldo A, Puleo S, Licata A. Evaluation of the prognostic accuracy of Astler-Coller's and Jass' classifications of colorectal cancer. Tumori 2001; 87: 127-129.
19. De Quay N, Cerottini JP, Albe X, Saraga E, Givel JC, Caplin S. Prognosis in Dukes' B colorectal carcinoma: the Jass classification revisited. Eur J Surg 1999; 165: 588-592.
20. Ilyas M, Novelli M, Wilkinson K, et al. Tumour recurrence is associated with Jass grouping but not with differences in E-cadherin expression in moderately differentiated Dukes' B colorectal cancers. J Clin Pathol 1997; 50: 218-222.
21. Szynglarewicz B, Matkowski R, Suder E, et al. Predictive value of lymphocytic infiltration and character of invasive margin following total mesorectal excision with sphincter preservation for the high-risk carcinoma of the rectum. Adv Med Sci 2007; 52: 159-163.
22. Harrison JC, Dean PJ, el-Zeky F, Vander Zwaag R. From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol 1994; 25: 498-505.
23. Fisher ER, Robinsky B, Sass R, Fisher B. Relative prognostic value of the Dukes and the Jass systems in rectal cancer. Findings from the National Surgical Adjuvant Breast and Bowel Projects (Protocol R-01). Dis Colon Rectum 1989; 32: 944-949.
24. Deans GT, Heatley M, Anderson N, et al. Jass' classification revisited. J Am Coll Surg 1994; 179: 11-17.
25. Mitry E, Benhamiche AM, Jouve JL, Clinard F, Finn-Faivre C, Faivre J. Colorectal adenocarcinoma in patients 45 years of age: comparison with older patients in a well-defined French population. Dis Colon Rectum 2001; 44: 380-387.
26. Cerottini JP, Caplin S, Pampallona S, Givel JC. Prognostic factors in colorectal cancer. Oncol Rep 1999; 6: 409-414.
27. Jatzko GR, Jagoditsch M, Lisborg PH, Denk H, Klimpfinger M, Stettner HM. Long-term results of radical surgery for rectal cancer: multivariate analysis of prognostic factors influencing survival and local recurrence. Eur J Surg Oncol 1999; 25: 284-291.
28. Weissenberger C, Geissler M., Otto F, et al. Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002). World J Gastroenterol 2006; 12: 1849-1858.
29. Staudacher C, Chiappa A, Zbar AP, Bertani E, Biella F. Curative resection for colorectal cancer in the elderly. Prognostic factors and five-year follow-up. Ann Ital Chir 2000; 71: 491-496.
30. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097.
31. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17: 2412-2418.